日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR-ABL-Positive Leukemia

SOS1 的靶向降解表现出强大的抗癌活性并克服了 KRAS 突变肿瘤和 BCR-ABL 阳性白血病的耐药性

Ziwei Luo #, Chencen Lin #, Chuwei Yu, Changxian Yuan, Wenyong Wu, Xiaowei Xu, Renhong Sun, Yan Jia, Yafang Wang, Jie Shen, Dingyan Wang, Sinan Wang, Hualiang Jiang, Biao Jiang, Xiaobao Yang, Chengying Xie

MiR-552-3p Regulates Multiple Fibrotic and Inflammatory genes Concurrently in Hepatic Stellate Cells Improving NASH-associated Phenotypes

MiR-552-3p 同时调控肝星状细胞中的多种纤维化和炎症基因,改善 NASH 相关表型

Ningning Ma, Aijun Hou, Xiangyu Pan, Fuguang Sun, Xiaoding Xu, Chuwei Yu, Rongtao Lai, Ruimin Huang, Likun Gong, Qing Xie, Jing Chen, Jin Ren

MiR-337-3p improves metabolic-associated fatty liver disease through regulation of glycolipid metabolism

MiR-337-3p 通过调节糖脂代谢改善代谢相关脂肪肝疾病

Xiaoding Xu, Chuwei Yu, Hongxiu He, Xiangyu Pan, Aijun Hou, Jianxun Feng, Rongrong Tan, Likun Gong, Jing Chen, Jin Ren

MicroRNA-379-5p regulates free cholesterol accumulation and relieves diet induced-liver damage in db/db mice via STAT1/HMGCS1 axis

MicroRNA-379-5p 通过 STAT1/HMGCS1 轴调节 db/db 小鼠的游离胆固醇积累并减轻饮食引起的肝损伤

Yunxia Dong #, Chuwei Yu #, Ningning Ma, Xiaoding Xu, Qian Wu, Henglei Lu, Likun Gong, Jing Chen, Jin Ren

MiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice

MiR-337-3p 通过靶向 PCSK9 降低高脂血症小鼠血清 LDL-C 水平

Xiaoding Xu, Yunxia Dong, Ningning Ma, Weiwen Kong, Chuwei Yu, Likun Gong, Jing Chen, Jin Ren

New PCSK9 inhibitor miR-552-3p reduces LDL-C via enhancing LDLR in high fat diet-fed mice

新型 PCSK9 抑制剂 miR-552-3p 通过增强高脂饮食小鼠的 LDLR 来降低 LDL-C

Ningning Ma, Lei Fan, Yunxia Dong, Xiaoding Xu, Chuwei Yu, Jing Chen, Jin Ren